Recent developments in boron neutron capture therapy

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The development of tumour-specific, boron-containing drugs will play an important role if boron neutron capture therapy (BNCT) is to evolve into a clinically accepted treatment for cancer. BNCT is a binary cancer therapy, which is dependent on the selective deposition of boron-10 in a tumour cell followed by exposure of the cell to a neutron flux of appropriate energy. Over the past four decades, significant advances have been made in nuclear physics and nuclear engineering such that the required neutron sources are now available at a few centres throughout the world. The development of tumour-specific, boronated agents has met with more limited success although BNCT clinical trials have been initiated in the USA, Europe and Japan. This review focuses on patents published from 1995 through 1997 dealing with boronated agents, which could prove useful in clinical BNCT.

Original languageEnglish (US)
Pages (from-to)545-551
Number of pages7
JournalExpert Opinion on Therapeutic Patents
Volume8
Issue number5
DOIs
StatePublished - May 14 1998
Externally publishedYes

Fingerprint

Boron Neutron Capture Therapy
Boron
Neutrons
Neoplasms
Nuclear Physics
Patents
Japan
Clinical Trials
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Recent developments in boron neutron capture therapy. / Kabalka, George.

In: Expert Opinion on Therapeutic Patents, Vol. 8, No. 5, 14.05.1998, p. 545-551.

Research output: Contribution to journalReview article

@article{35e7c9431adb456d9cdf31d41e10e9b6,
title = "Recent developments in boron neutron capture therapy",
abstract = "The development of tumour-specific, boron-containing drugs will play an important role if boron neutron capture therapy (BNCT) is to evolve into a clinically accepted treatment for cancer. BNCT is a binary cancer therapy, which is dependent on the selective deposition of boron-10 in a tumour cell followed by exposure of the cell to a neutron flux of appropriate energy. Over the past four decades, significant advances have been made in nuclear physics and nuclear engineering such that the required neutron sources are now available at a few centres throughout the world. The development of tumour-specific, boronated agents has met with more limited success although BNCT clinical trials have been initiated in the USA, Europe and Japan. This review focuses on patents published from 1995 through 1997 dealing with boronated agents, which could prove useful in clinical BNCT.",
author = "George Kabalka",
year = "1998",
month = "5",
day = "14",
doi = "10.1517/13543776.8.5.545",
language = "English (US)",
volume = "8",
pages = "545--551",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Recent developments in boron neutron capture therapy

AU - Kabalka, George

PY - 1998/5/14

Y1 - 1998/5/14

N2 - The development of tumour-specific, boron-containing drugs will play an important role if boron neutron capture therapy (BNCT) is to evolve into a clinically accepted treatment for cancer. BNCT is a binary cancer therapy, which is dependent on the selective deposition of boron-10 in a tumour cell followed by exposure of the cell to a neutron flux of appropriate energy. Over the past four decades, significant advances have been made in nuclear physics and nuclear engineering such that the required neutron sources are now available at a few centres throughout the world. The development of tumour-specific, boronated agents has met with more limited success although BNCT clinical trials have been initiated in the USA, Europe and Japan. This review focuses on patents published from 1995 through 1997 dealing with boronated agents, which could prove useful in clinical BNCT.

AB - The development of tumour-specific, boron-containing drugs will play an important role if boron neutron capture therapy (BNCT) is to evolve into a clinically accepted treatment for cancer. BNCT is a binary cancer therapy, which is dependent on the selective deposition of boron-10 in a tumour cell followed by exposure of the cell to a neutron flux of appropriate energy. Over the past four decades, significant advances have been made in nuclear physics and nuclear engineering such that the required neutron sources are now available at a few centres throughout the world. The development of tumour-specific, boronated agents has met with more limited success although BNCT clinical trials have been initiated in the USA, Europe and Japan. This review focuses on patents published from 1995 through 1997 dealing with boronated agents, which could prove useful in clinical BNCT.

UR - http://www.scopus.com/inward/record.url?scp=0031943052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031943052&partnerID=8YFLogxK

U2 - 10.1517/13543776.8.5.545

DO - 10.1517/13543776.8.5.545

M3 - Review article

VL - 8

SP - 545

EP - 551

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 5

ER -